NCPA applauds House passage of PATIENT Act
By HME News Staff
Updated 9:32 AM CDT, Thu May 25, 2023
WASHINGTON – The National Community Pharmacists Association welcomes the passage of the Promoting Access to Treatments and Increasing Extremely Needed Transparency (PATIENT) Act, H.R. 3561, by the House Energy and Commerce Committee. The PATIENT Act, which passed the committee 49-0, includes several provisions vital to lowering prescription drug costs and bringing transparency to the practices of pharmacy benefit managers, the NCPA says. “Patients and community pharmacies have been advocating aggressively for years for reforms and insight into PBM practices,” said Anne Cassity, senior vice president of government affairs at NCPA. “This comprehensive package would take significant strides forward in terms of federal oversight, and NCPA is proud to support it. We’re grateful to the committee for its work and hope the full House will soon advance it.” NCPA-supported provisions within the bill include: The Drug Price Transparency in Medicaid Act (H.R. 1613); The PBM Accountability Act (H.R. 2679); and The Promoting Transparency and Healthy Competition in Medicare Act (H.R. 3282).
Comments